Endovascular Treatment Devices Market Offers Lucrative Opportunities

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Endovascular Treatment Devices Market Size, Share & Trends Analysis Report By Product (Percutaneous Endovascular Aneurysm Repair (EVAR), Fenestrated EVAR, Aortic Stents Biodegradable Stents, Self- Expanding Nitinol Stents, Thoracic Aortic Aneurysm Grafts), By Procedure (Ballon Angioplasty, Angioplasty With Stent Replacement, Drug-Eluting Stents Renal Artery Angioplasty and Stenting Carotid Artery, Thrombosis, Renal Artery Angioplasty and Stenting, Transfemoral Carotid Artery Revascularization, Intravascular Brachytherapy, Carotid Artery Stenting), By Application (Pulmonary, Vascular, Cardiology Surgery, Neurology And Radiology), - Market Outlook And Industry Analysis 2031"

The Global Endovascular Treatment Devices Market is valued at US$ 3.26 Billion in 2023, and it is expected to reach US$ 6.54 Billion by 2031, with a CAGR of 9.19% during the forecast period of 2024-2031.

Request Complete FREE Sample Report Click Here: https://www.insightaceanalytic.com/request-sample/1364

Endovascular treatment devices have revolutionized the landscape of vascular medicine by offering minimally invasive solutions for a variety of conditions. These devices, such as stent grafts for abdominal aortic aneurysm repair and mechanical thrombectomy devices for acute ischemic stroke treatment, enable surgeons to access and treat affected blood vessels through small incisions. This approach not only reduces recovery times and hospital stays but also lowers the risks associated with traditional open surgeries. As the global population ages and the incidence of vascular diseases rises, the demand for these advanced devices continues to grow. Moreover, advancements in device technology further enhance their effectiveness and expand their applications across different cardiovascular conditions, including coronary artery disease and peripheral artery disease.

Looking forward, the market for endovascular treatment devices is poised for significant expansion. Factors such as increasing prevalence of vascular diseases, rising adoption of minimally invasive procedures, and ongoing innovations in device design are driving this growth. These devices not only improve patient outcomes but also contribute to healthcare cost-effectiveness by reducing procedural complications and recovery times. As medical research continues to push boundaries in device innovation and treatment techniques, the role of endovascular treatment devices in modern medicine is set to expand, offering new hope and improved quality of life for patients worldwide.

List of Prominent Players in the Endovascular Treatment Devices Market:

• Cardinal Health
• Endospan
• Geting AB
• Bosten Scientific Corporation
• Inspire MD
• Japan Lifeline Co., Ltd.
• Medtronic
• Lombord Medical
• Penumbra, Inc.
• Terumo Corporation

Market Dynamics:

Drivers-

The global market for endovascular treatment devices is booming, fueled by a rising prevalence of cardiovascular diseases, which claim an estimated 17.9 million lives annually according to WHO. This includes conditions like coronary artery disease, peripheral artery disease, and acute ischemic strokes, driving demand for minimally invasive devices such as stent grafts, catheters, and thrombectomy devices. Concurrently, the increasing incidence of abdominal aortic aneurysms worldwide is accelerating adoption of minimally invasive endovascular aneurysm repair procedures like percutaneous endovascular aneurysm repair (PEVAR) and transcatheter aortic valve repair (TAVR), known for reducing recovery times and hospital stays. Advancements in technology and ongoing R&D efforts are enhancing device efficacy and safety, catering to the healthcare needs of an aging population and bolstering market growth alongside rising healthcare expenditures in developed economies.

Challenges:

High costs associated with endovascular surgeries and devices pose barriers to adoption, impacting healthcare providers and patients. A shortage of skilled surgeons capable of performing complex procedures further limits market growth, while stringent regulatory requirements delay the introduction of innovative devices, hindering industry advancement.

Regional Trends:

North America's leadership in the endovascular treatment devices market is driven by several key factors. The region's high prevalence of cardiovascular diseases, including coronary artery disease, peripheral artery disease, and acute ischemic strokes, underscores the significant demand for advanced treatment options. According to the American Heart Association, cardiovascular diseases remain the leading cause of death in the United States, with 928,741 deaths reported in 2020 alone. Additionally, the aging population in North America contributes to a rising incidence of abdominal aortic aneurysms (AAA), further boosting demand for endovascular devices. Favorable reimbursement policies in the United States and Canada support market growth, while well-established healthcare infrastructure and a skilled workforce enable the proficient delivery of complex procedures.

Recent Developments:

• In July 2024, Endospan secured up to $25 million in loans from Artivion to support the FDA approval process for their Nexus Stent Graft System. Nexus is an off-the-shelf endovascular system aimed at treating aortic arch disease, encompassing aortic aneurysms and aortic dissection. The funding will enable Endospan to advance clinical trials and regulatory efforts necessary to bring this innovative treatment option to market in the United States.

• In April 2024, Getinge received EU MDR approval for its Advanta V12 covered stent system, tailored for treating patients with renal artery stenosis and aortoiliac occlusive disease, including lesions at the aortic bifurcation. This certification confirms compliance with European medical device regulations, underscoring Getinge's dedication to quality and patient safety in vascular interventions.

• In March 2024, Medtronic plc (NYSE: MDT) has FDA-approved its Evolut™ FX+ TAVR system for treating symptomatic severe aortic stenosis. This updated system retains the performance benefits of the Evolut platform and improves coronary access capabilities, offering enhanced treatment options for patients in the U.S.

Segmentation of Endovascular Treatment Devices Market-

By Product:

• Percutaneous Endovascular Aneurysm Repair (EVAR)
• Fenestrated EVAR
• Aortic Stents Biodegradable Stents
• Self- Expanding Nitinol Stents
• Thoracic Aortic Aneurysm Grafts
• Other Devices

By Procedure:

• Ballon Angioplasty
• Angioplasty With Stent Replacement
• Drug-Eluting Stents Renal Artery Angioplasty and Stenting Carotid Artery
• Thrombosis
• Renal Artery Angioplasty and Stenting
• Transfemoral Carotid Artery Revascularization
• Intravascular Brachytherapy
• Carotid Artery Stenting

By Application:

• Pulmonary
• Vascular
• Cardiology Surgery
• Neurology
• Radiology

By Region-

North America-

• The US
• Canada
• Mexico

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa
• Rest of Middle East and Africa